Overview

INvestigating TELmisartin Study

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.

Phase:

Phase 2

Details

Lead Sponsor:

University of Hawaii

Collaborator:

Queens Medical Center

Treatments:

Telmisartan